乙型肝炎病毒相关慢加急性肝衰竭评分模型及检验参数对诊断及预后影响的研究进展  

Scoring models and test indexes for diagnosis and prognosis of hepatitis B virus-related acute-on-chronic liver failure

作　　者：吴悦嘉 谢青 刘玉盒 陈小勇[2] 闫雪华[2] Yue-Jia Wu;Qing Xie;Yu-He Liu;Xiao-Yong Chen;Xue-Hua Yan(College of Medical Laboratory,Dalian Medical University,Dalian 116044,Liaoning Province,China;Department of Hepatology,The Second People’s Hospital of Lanzhou City,Lanzhou 730030,Gansu Province,China)

机构地区：[1]大连医科大学检验医学院,辽宁省大连市116044 [2]兰州市第二人民医院肝病科,甘肃省兰州市730030

出　　处：《世界华人消化杂志》2023年第6期207-213,共7页World Chinese Journal of Digestology

基　　金：兰州市人才创新创业,No.2021-RC-128.

摘　　要：乙肝相关慢加急性肝衰竭(hepatitis B virus relatedacute-on-chronic liver failure,HBV-ACLF)是肝衰竭的常见类型,可发生在慢性乙型病毒性肝炎或肝硬化代偿期或失代偿期的基础上,其病情进展快速,常合并肝、脑、心、肾、凝血等多器官功能衰竭的临床综合征,病死率极高.美国胃肠病学会(American Gastroenterological Association,ACG)将其定义为具有潜在可逆性疾病,早期诊断,规范治疗,将极大影响其预后.近年来,一些新的评分模型及生物标志物的临床应用,有效提高了对HBV-ACLF的诊断及预后判断.本文对目前临床应用较广的评分模型及检验参数进行了梳理,进一步探讨其对HBV-ACLF的诊断和预后影响的价值.Hepatitis B virus-associated acute-on-chronic liver failure(HBV-ACLF)is a common type of liver failure,which can occur in the context of chronic hepatitis B or cirrhosis compensatory period or decompensated period.HBV-ACLF progresses rapidly,is often complicated with multiple organ failure syndrome involving the liver,brain,heart,kidney,etc.,and is associated with an extremely high short-term mortality rate.The American College of Gastroenterology(ACG)defines HBV-ACLF as a potentially reversible disease,and early diagnosis and standardized treatment will affect its prognosis.In recent years,the clinical application of some new scoring models and biomarkers has effectively improved the diagnosis and prognosis of HBV-ACLF.This article reviews some scoring models and test indexes recently used in the clinical treatment and explores their value in the diagnosis and prognosis of HBV-ACLF.

关 键 词：慢加急性肝衰竭 乙型肝炎病毒 诊断价值 

分 类 号：R512.62[医药卫生—内科学] R575.3[医药卫生—临床医学]